Physician profile
Albert Chao
NPI 1225020068
$1,031.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.97 · 2020: $201 · 2021: $426 · 2022: $158 · 2023: $77.80 · 2024: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.46 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.68 | 2020-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $273.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $154.00 | 2020-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.90 | 2019 | |
| Amgen INC. | $36.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $36.10 | 2020 | |
| Viiv Healthcare Company | $33.33 | 2024 | Rukobia |
| Lilly USA, LLC | $30.39 | 2020 | |
| Abbvie INC. | $24.73 | 2024 | |
| Abbott Laboratories | $23.25 | 2024 | Eterna |
| Ultragenyx Pharmaceutical INC. | $20.92 | 2022 | |
| Medtronic, INC. | $18.99 | 2021 | |
| Shire North American Group INC | $15.07 | 2019 | |
| Amarin Pharma, INC. | $13.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.